Restoring blood coagulation in patients
taking Factor Xa Direct Oral Anticoagulants
(FXa-DOACs)

About VarmX

Our focus lies in the development of a breakthrough, swift-acting, and convenient universal bypassing agent that restores blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs).

We aim to stop severe bleeding and eliminate bleeding risk during surgery in patients taking FXa DOACs.

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio

News & events

All news
  • News

VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001

Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling...

  • News

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities VarmX shareholders to receive initial $117m...

All news